What are the limitations of the ebmt risk score?

While the ebmt risk score is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the ebmt risk score to ensure safe bedside use and optimal diagnostic accuracy.

How does the ebmt risk score compare to other hematology scores?

The ebmt risk score is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the ebmt risk score free to use?

Yes. OpiCalc provides the ebmt risk score completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

EBMT Risk Score

EBMT Risk Score: The Gratwohl score for allogeneic HSCT. Predicts survival and transplant-related mortality using universal pre-transplant factors.

Age at Transplant

Disease Stage

Donor Type

Time: Diagnosis to Tx

Donor/Recipient Sex

Total EBMT Risk Score

0

Estimated Survival Probability

High (~70%)

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Initial risk stratification for patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Predicting Transplant-Related Mortality (TRM) and Overall Survival (OS) pre-transplant.

Counselling patients regarding the relative risks of different transplant strategies (e.g., sibling vs. unrelated donor).

Patient Population

Derived and validated in adult patients with hematologic malignancies (CML, AML, ALL, MDS, Myeloma, Lymphoma) across EBMT-affiliated centers.

When Not to Rely on This Score Alone

Non-malignant conditions (e.g., Sickle Cell Disease) — the score weighting is malignant-specific.

Reduced Intensity Conditioning (RIC) — the score was primarily developed in the mieloablative era, though it remains broadly discriminative.

Pediatric patients — age-related risks and donor outcomes differ in children.

Section 2

Formula & Logic

Scoring Components

Factor	Score 0	Score 1	Score 2
Age (yr)	< 20	20 - 40	> 40
Disease Stage	Early	Intermediate	Late
Time to Tx	< 12 months	> 12 months	-
Donor Type	HLA-Identical Sibling	Unrelated	-
Donor/Recip Sex	Other	Female Donor to Male Recipient	-

Defining Stages

Early: CR1 (AML, ALL, NHL), CP1 (CML), or Untreated (MDS).

Intermediate: CR2/CR3 or Intermediate Phases.

Late: Active disease at transplant, Relapsed/Refractory, or Blast Crisis.

Section 3

Pearls/Pitfalls

The "Female to Male" Factor

The 1 point assigned to a female donor for a male recipient reflects the historical observation of increased GVHD risk and higher TRM in this configuration, likely due to H-Y antigen sensitization.

Section 4

Evidence Appraisal

Primary Score

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the EBMT.

Gratwohl A et al. • Lancet. 1998;352(9134):1087-92.

View Source

The EBMT risk score.

Gratwohl A et al. • Bone Marrow Transplantation. 2009;44(8):433-8. Validation in 56,000+ patients across all diseases.

View Source

Section 5

Literature

Development

Developed by Alois Gratwohl and the EBMT group. Initially focused on CML, it was subsequently expanded and validated as a "universal" transplant risk score.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Initial risk stratification for patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Predicting Transplant-Related Mortality (TRM) and Overall Survival (OS) pre-transplant.

Counselling patients regarding the relative risks of different transplant strategies (e.g., sibling vs. unrelated donor).

Patient Population

Derived and validated in adult patients with hematologic malignancies (CML, AML, ALL, MDS, Myeloma, Lymphoma) across EBMT-affiliated centers.

When Not to Rely on This Score Alone

Non-malignant conditions (e.g., Sickle Cell Disease) — the score weighting is malignant-specific.

Reduced Intensity Conditioning (RIC) — the score was primarily developed in the mieloablative era, though it remains broadly discriminative.

Pediatric patients — age-related risks and donor outcomes differ in children.

Section 2

Formula & Logic

Scoring Components

Factor	Score 0	Score 1	Score 2
Age (yr)	< 20	20 - 40	> 40
Disease Stage	Early	Intermediate	Late
Time to Tx	< 12 months	> 12 months	-
Donor Type	HLA-Identical Sibling	Unrelated	-
Donor/Recip Sex	Other	Female Donor to Male Recipient	-

Defining Stages

Early: CR1 (AML, ALL, NHL), CP1 (CML), or Untreated (MDS).

Intermediate: CR2/CR3 or Intermediate Phases.

Late: Active disease at transplant, Relapsed/Refractory, or Blast Crisis.

Section 3

Pearls/Pitfalls

The "Female to Male" Factor

The 1 point assigned to a female donor for a male recipient reflects the historical observation of increased GVHD risk and higher TRM in this configuration, likely due to H-Y antigen sensitization.

Section 4

Evidence Appraisal

Primary Score

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the EBMT.

Gratwohl A et al. • Lancet. 1998;352(9134):1087-92.

View Source

The EBMT risk score.

Gratwohl A et al. • Bone Marrow Transplantation. 2009;44(8):433-8. Validation in 56,000+ patients across all diseases.

View Source

Section 5

Literature

Development

Developed by Alois Gratwohl and the EBMT group. Initially focused on CML, it was subsequently expanded and validated as a "universal" transplant risk score.

Last Comprehensive Review: 2026

Related Hematology Tools

PCNSL MSKCC Score

ISS

R-ISS

IMWG Response Criteria

MRD Assessment Threshold Interpreter

mSMART 3.0

SLiM-CRAB Criteria

Durie-Salmon Staging

AL Amyloidosis Staging

HCT-CI

Have feedback about this calculator?Let us know.

EBMT Risk Score

EBMT Risk Score: The Gratwohl score for allogeneic HSCT. Predicts survival and transplant-related mortality using universal pre-transplant factors.

Age at Transplant

Disease Stage

Donor Type

Time: Diagnosis to Tx

Donor/Recipient Sex

Total EBMT Risk Score

0

Estimated Survival Probability

High (~70%)

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Initial risk stratification for patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Predicting Transplant-Related Mortality (TRM) and Overall Survival (OS) pre-transplant.

Counselling patients regarding the relative risks of different transplant strategies (e.g., sibling vs. unrelated donor).

Patient Population

Derived and validated in adult patients with hematologic malignancies (CML, AML, ALL, MDS, Myeloma, Lymphoma) across EBMT-affiliated centers.

When Not to Rely on This Score Alone

Non-malignant conditions (e.g., Sickle Cell Disease) — the score weighting is malignant-specific.

Reduced Intensity Conditioning (RIC) — the score was primarily developed in the mieloablative era, though it remains broadly discriminative.

Pediatric patients — age-related risks and donor outcomes differ in children.

Section 2

Formula & Logic

Scoring Components

Factor	Score 0	Score 1	Score 2
Age (yr)	< 20	20 - 40	> 40
Disease Stage	Early	Intermediate	Late
Time to Tx	< 12 months	> 12 months	-
Donor Type	HLA-Identical Sibling	Unrelated	-
Donor/Recip Sex	Other	Female Donor to Male Recipient	-

Defining Stages

Early: CR1 (AML, ALL, NHL), CP1 (CML), or Untreated (MDS).

Intermediate: CR2/CR3 or Intermediate Phases.

Late: Active disease at transplant, Relapsed/Refractory, or Blast Crisis.

Section 3

Pearls/Pitfalls

The "Female to Male" Factor

The 1 point assigned to a female donor for a male recipient reflects the historical observation of increased GVHD risk and higher TRM in this configuration, likely due to H-Y antigen sensitization.

Section 4

Evidence Appraisal

Primary Score

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the EBMT.

Gratwohl A et al. • Lancet. 1998;352(9134):1087-92.

View Source

The EBMT risk score.

Gratwohl A et al. • Bone Marrow Transplantation. 2009;44(8):433-8. Validation in 56,000+ patients across all diseases.

View Source

Section 5

Literature

Development

Developed by Alois Gratwohl and the EBMT group. Initially focused on CML, it was subsequently expanded and validated as a "universal" transplant risk score.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Initial risk stratification for patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Predicting Transplant-Related Mortality (TRM) and Overall Survival (OS) pre-transplant.

Counselling patients regarding the relative risks of different transplant strategies (e.g., sibling vs. unrelated donor).

Patient Population

Derived and validated in adult patients with hematologic malignancies (CML, AML, ALL, MDS, Myeloma, Lymphoma) across EBMT-affiliated centers.

When Not to Rely on This Score Alone

Non-malignant conditions (e.g., Sickle Cell Disease) — the score weighting is malignant-specific.

Reduced Intensity Conditioning (RIC) — the score was primarily developed in the mieloablative era, though it remains broadly discriminative.

Pediatric patients — age-related risks and donor outcomes differ in children.

Section 2

Formula & Logic

Scoring Components

Factor	Score 0	Score 1	Score 2
Age (yr)	< 20	20 - 40	> 40
Disease Stage	Early	Intermediate	Late
Time to Tx	< 12 months	> 12 months	-
Donor Type	HLA-Identical Sibling	Unrelated	-
Donor/Recip Sex	Other	Female Donor to Male Recipient	-

Defining Stages

Early: CR1 (AML, ALL, NHL), CP1 (CML), or Untreated (MDS).

Intermediate: CR2/CR3 or Intermediate Phases.

Late: Active disease at transplant, Relapsed/Refractory, or Blast Crisis.

Section 3

Pearls/Pitfalls

The "Female to Male" Factor

The 1 point assigned to a female donor for a male recipient reflects the historical observation of increased GVHD risk and higher TRM in this configuration, likely due to H-Y antigen sensitization.

Section 4

Evidence Appraisal

Primary Score

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the EBMT.

Gratwohl A et al. • Lancet. 1998;352(9134):1087-92.

View Source

The EBMT risk score.

Gratwohl A et al. • Bone Marrow Transplantation. 2009;44(8):433-8. Validation in 56,000+ patients across all diseases.

View Source

Section 5

Literature

Development

Developed by Alois Gratwohl and the EBMT group. Initially focused on CML, it was subsequently expanded and validated as a "universal" transplant risk score.

Last Comprehensive Review: 2026

Related Hematology Tools

PCNSL MSKCC Score

ISS

R-ISS

IMWG Response Criteria

MRD Assessment Threshold Interpreter

mSMART 3.0

SLiM-CRAB Criteria

Durie-Salmon Staging

AL Amyloidosis Staging

HCT-CI

Have feedback about this calculator?Let us know.